Printer Friendly

ANTITOPE ENTERS RESEARCH AGREEMENT WITH ANNEXON.

Antitope Ltd a PolyTherics company, has entered a research agreement with Annexon to generate novel antibody therapeutics for the treatment of neurodegenerative diseases.

Under the terms of the agreement Annexon will provide antibodies against specific components of the complement system and Antitope will use its Composite Human Antibody technology to generate a series of fully humanised antibodies devoid of T cell epitopes and with a consequent low risk of clinical immunogenicity. Annexon will screen the Composite Human Antibodies provided by Antitope and select a lead antibody to take forward into further preclinical and clinical studies. Annexon's most advanced programme is for an orphan autoimmune neurological indication. The antibodies are expected to halt the progression of disease and allow the body to repair.

About Antitope

Antitope Limited is a subsidiary of PolyTherics Limited, a group which focuses on providing services and technologies to enable the development of better biopharmaceuticals. Antitope undertakes immunogenicity testing of antibodies and other proteins, engineering of antibodies and proteins to reduce their immunogenicity, and development of manufacturing cell lines. Antitope's proprietary technologies include: EpiScreen for analysis of immunogenicity; Composite Human Antibody and Composite Protein technologies to generate fully humanised antibodies and proteins; and Composite CHO technology to produce high yielding manufacturing cell lines for transfer to GMP manufacturers. Antitope has multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide and has successfully completed over 100 projects for its partners. For more information, visit www.antitope.co.uk.

About Annexon

Annexon was founded in 2011 by Arnon Rosenthal, Ph.D., formerly an executive investigator with Genentech for 16 years, and a Co-Founder, President and Chief Scientific Officer of Rinat Neurosciences (acquired by Pfizer), and Ben Barres, M.D., Ph.D., a prominent neuroscientist, currently Professor and Chair of Neurobiology at Stanford University School of Medicine, and a Member of the National Academy of Sciences.

Annexon's mission is to develop a new class of drugs to inhibit the complement system and halt the progression of multiple neurodegenerative disorders including Alzheimer's disease, glaucoma, Parkinson's disease, spinal muscular atrophy, stroke, traumatic brain injury, multiple sclerosis, neuromyelitis optica and peripheral nervous system diseases including Guillain-Barre

syndrome and myasthenia gravis. Annexon was founded on the belief that the complement system is a key mechanism of neurodegenerative disease.

About PolyTherics

PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development.

PolyTherics' portfolio of services and technologies includes proprietary site-specific conjugation technologies and novel polymers for optimising the therapeutic properties of biopharmaceuticals and through its Cambridge, UK-based subsidiary, Antitope, services for protein immunogenicity assessment and antibody and protein re- engineering technologies are delivered. The group provides its services and technologies to an international client base that includes most of the world's leading biotechnology and pharmaceutical companies.

PolyTherics is a privately owned UK company backed by institutional investors including Imperial Innovations (AIM: IVO), Invesco Perpetual, Mercia Fund Management, Advantage Enterprise & Innovation Fund (managed by Catapult Venture Partners), ProVen Health, Oxford Technology VCTs and high net worth individuals' funds managed by Longbow Capital. The Company has dedicated facilities in London, Cambridge and Coventry, UK.

For more information, visit www.polytherics.com or call 650/544-8750.
COPYRIGHT 2014 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:4EUUK
Date:Jan 1, 2014
Words:538
Previous Article:BIOGEN AND SOBI PARTNER IN STUDY.
Next Article:ISARNA SIGNS MANUFACTURING AGREEMENT WITH SANOFI.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters